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Monoclonal antibodies (mAbs) are established therapies for many conditions, including cancers, auto-
immune conditions and infectious diseases. mAbs can offer beneﬁts over conventional pharmacotherapy
in terms of potency, dosing frequency and speciﬁcity for their target antigen. Mouse-derived antibodies
were initially used in humans; however, patients often developed human anti-mouse antibodies,
resulting in rapid antibody clearance (and a resulting loss of efﬁcacy) and hypersensitivity reactions.
Chimeric, humanized, and fully human antibodies were thus developed, with increasing amounts of
human sequence, to reduce immunogenicity. Although generally well tolerated, mAbs may be associated
with adverse events (AEs). Many AEs are target-related, and will be speciﬁc to the antibody target and
the therapeutic area of use. However, off-target AEs, such as hypersensitivity reactions, are observed with
many antibodies.
Within the realm of cardiovascular medicine, new antibody-based therapies are under investigation to
reduce low-density lipoprotein cholesterol (LDL-C) levels. Proprotein convertase subtilisin/kexin type 9
(PCSK9) regulates plasma LDL-C levels by increasing degradation of the LDL receptor (LDLR). Therefore,
inhibition of the interaction between PCSK9 and the LDLR with mAbs targeting PCSK9 has great potential
for patients with hypercholesterolaemia. Early clinical phase studies suggest these mAbs are effective
and well tolerated; however, further studies are required to assess their long-term safety.
 2013 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.Contents
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Cardiovascular diseases (CVDs) are a leading cause of morbidity
and mortality worldwide, accounting for approximately 30% of all
deaths in 2008 [1]. A correlation between the level of low-density
lipoprotein cholesterol (LDL-C) and the rate of cardiovascular (CV)
events has been demonstrated in several studies, and lowering LDL-
C levels dramatically reduces the incidence of CV events [2e4].
Consequently, international treatment guidelines recommend
lowering LDL-C to <2.5 mmol/L (<97 mg/dL) in most patients with
established CVDs and to <1.8 mmol/L (<70 mg/dL) in those at very
high risk for CV events [5e7]. Recent studies also suggest that sig-
niﬁcant additional reductions in CV risk can be obtained by reducing
LDL-C levels beyond those currently recommended [8e11].
Despite the widespread availability of effective lipid-lowering
agents such as statins, 16e53% of patients worldwide fail to ach-
ieve their lipid targets [12e14], with even higher rates (79%) in
patients with familial forms of hypercholesterolaemia [15].
Approximately 20 million patients in America take statins [16] and,
approximately 10e20% of patients are unable to tolerate statins,
particularly at the higher doses required to achieve LDL-C goals
[17]. New treatments that aggressively reduce lipid levels in pa-
tients with severe hypercholesterolaemia, or those unable to reach
their lipid targets, are therefore required. Some newer therapies in
development for hypercholesterolaemia are utilizing monoclonal
antibodies (mAbs), rather than small molecule inhibitors, to
address novel targets.
Since their initial introduction into clinical practice in 1986,
mAbs have become established therapies for a wide range of con-
ditions, including cancers, transplant rejection, autoimmune con-
ditions and infectious diseases [18e26]. Advances in molecular
biology techniques and mammalian cell-line expression systems
during the 1980s and 1990s led to the production of better tolerated,
more target-speciﬁc mAbs with reduced immunogenicity and lon-
ger half-lives [19,27]. This class of biotherapeutic drugs has obvious
advantages over conventional small-molecule pharmacotherapy in
termsof potency, speciﬁcity and dosing frequency. Due to their large
size, mAbs are not expected to inhibit cardiac potassium ion/human
ether-à-go-go related gene (hERG) channels, thus may not lead to
QT interval changes [28]. Furthermore, mAbs do not traditionally
interact with the cytochrome P450 isoenzyme or other transport
proteins in the body, resulting in a greatly reduced potential for
drugedrug interactions with other agents. Generally mAbs are well
tolerated [29,30]; however, as with all agents, mAbs may be asso-
ciated with adverse events (AEs) as a result of enhancing/inhibiting
the activity of the target molecule on the target tissue, or due to
interactions of the mAbwith target molecules on tissues other than
the intended ones [18,29,31e33]. It is therefore important to un-
derstand the mechanism of action by which each mAb elicits its
therapeutic effect, to reduce its potential immunogenicity through
genetic engineering [18,30,34,35] and to thoroughly assess the ef-
ﬁcacy and safety of each mAb in well-deﬁned pre-clinical studies
before embarking on clinical trials [35,36].
So far, more than 30mAbs have been approved for clinical use by
European and United States regulatory agencies, andmore than 200
are currently undergoing pre-clinical or clinical investigations
[19,26]. To date, the only mAb licensed for the treatment of patientswith CV-related disorders is abciximab, which targets the glyco-
protein IIb/III receptor and is used after percutaneous coronary
intervention and for unstable angina [21]. Small-molecule therapies
remain the most frequently used drug type in the CV therapy area;
however, a new class of mAbethe proprotein convertase subtilisin/
kexin type 9 (PCSK9) inhibitoreis being developed for the reduction
of LDL-C in subjects with hypercholesterolaemia [37,38]. If suc-
cessful, PCSK9mAbs have the potential to dramatically improve the
management of CV risk in patients who fail to achieve their thera-
peutic targets using existing lipid-lowering strategies.
This review examines the long-term safety evidence for mAbs
and discusses the implications for PCSK9 mAbs in the treatment of
hypercholesterolaemia.
2. The evolution of mAbs
mAbs rely on one of three functionalities to achieve their clinical
efﬁcacy: (i) target-speciﬁc binding by the Fab domain (antigen-
binding site) to enhance or suppress an important biological effect,
(ii) interaction of the Fc domain (constant domain)with cell-surface
receptors leading to immune-mediated effector functions, includ-
ing antibody-dependent cell-mediated cytotoxicity, complement-
dependent cytotoxicity, or antibody-dependent phagocytosis [18]
and (iii) deposition of complement on multimeric immune com-
plexes between the mAb and the target and subsequent activation
of complement-dependent cytotoxicity. The Fc determines the
functional characteristics of the antibody, including effector func-
tion activity. In situations where a mAb effector function is not
wanted, mAbs can be engineered in such a way that the Fc region is
modiﬁed or isotypes can be selected that are relatively poor at
inducing effector functions [18]. However, in general, soluble
monomeric targets are not subject to effector functions because
there is no multimerization of the antibody.
The production of speciﬁc antibodies from hybridoma cell lines
was ﬁrst described by Köhler and Milstein in 1975 [39]. The ﬁrst
mAb to be approved for use in humans was muromonab, a mouse
anti-CD3 immunoglobulin G2a antibody for the prophylaxis or
treatment of allograft rejection [40]. However, differences between
the human and mouse immune systems meant that patients trea-
ted with full mouse sequence mAbs often developed human anti-
mouse antibodies (HAMAs), resulting in rapid mAb clearance, hy-
persensitivity, poor target-site penetration and reduced efﬁcacy via
stimulation of cytotoxicity [24,40].
To reduce the risk of these events, chimeric and humanized
mAbs were produced by genetic engineering [41]. Chimeric mAbs,
such as abciximab [21], inﬂiximab (an anti-TNF used in rheumatoid
arthritis) [42] and rituximab (an anti-CD 20 used in rheumatoid
arthritis, non-Hodgkin’s lymphoma and chronic lymphocytic leu-
kaemia) [43] contain the antigen-binding variable domain (Fab)
from the species used for immunization (typically mouse), fused
onto the human constant domains (Fig. 1). Humanized mAbs, such
as daclizumab (an anti-CD 25 in development formultiple sclerosis)
[44] and omalizumab (anti-IgE used in asthma) [22], contain Fab
sequences with smaller amounts of mouse sequence fused on to
human constant domains (Fig. 1). Thus, compared with mouse and
chimeric mAbs, humanized molecules contain a greater proportion
of human sequence, which reduces the likelihood of HAMA
Fig. 1. The evolution of therapeutic mAbs.
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mouse mAbs can result in reduced binding afﬁnity for the thera-
peutic target. This necessitates the need for additional engineering
to increase afﬁnity through mutation of amino acids constituting
the complementarity-determining regions that bind the target [46].
More recently, fully human mAbs have been produced which,
compared with chimeric and humanized mAbs, generally have
reduced immunogenicity (Fig. 1) [19]. Fully human mAbs can be
produced from in vitro systems such as phage display libraries
[47,48] or from in vivo platforms, such as transgenic mice [49e51].
The ﬁrst of these techniques involves the recombinant expression of
human Fabs in a bacteriophage and the subsequent selection of
mAbs based on the required antigen-binding properties. The second
technique uses transgenic mice and involves the introduction of
human immunoglobulin genes into the murine genome. The
transgenic mouse is then immunized against a speciﬁc antigen,Table 1
Fully human monoclonal antibodies approved for use in Europe and the United
States.
International
non-proprietary name
Brand name Company Indication
Adalimumab [52] Humira Abbott Rheumatoid arthritis
Panitumumab [53] Vectibix Amgen Colourectal cancer
Golimumab [54] Simponi Centocor Rheumatoid and
psoriatic arthritis,
ankylosing spondylitis
Canakinumab [55] Ilaris Novartis MuckleeWells
syndrome
Ustekinumab [56] Stelara Johnson &
Johnson
Psoriasis
Ofatumumab [57] Arzerra Genmab Chronic lymphocytic
leukaemia
Denosumab [58] Prolia Amgen Bone loss
Belimumab [59] Benlysta Human Genome
Sciences
Systemic lupus
erythematosus
Ipilimumab [60] Yervoy Bristol-Myers
Squibb
Metastatic melanomawhich stimulates the production of human mAbs that can subse-
quently be isolated and cloned from the mouse B cells. Selection of
antibodies in vivo has an inherent advantage over in vitro selection
by phage display, because the antibody must fold and express efﬁ-
ciently, and have reasonable pharmacokinetic properties in order to
compete effectively with other antibodies for binding to antigen.
Overall, nine fully human mAbs are currently approved for use
in Europe and the United States [19,26] (Table 1).
Another, raxibacumab (an antibody against Bacillus anthracis
protective antigen for the treatment of anthrax), has been ﬁled for
approval and numerous other fully human mAbs are being
developed.
Additionally, the delivery method of antibodies has evolved.
Previously, most mAbswere injected intravenously as this results in
100% bioavailability, rapid delivery to the systemic circulation, and
high ﬁnal plasma concentrations. However, intravenous admin-
istration has limitations, such as the need for regular clinic visits,
which greatly increase the cost of therapy. Also, the rapid nature of
intravenous mAb delivery can cause more serious hypersensitivity
reactions in some patients. Many antibodies can now be delivered
subcutaneously. Furthermore, pre-ﬁlled syringes in auto-injector
devices can allow self-administration.3. Primary safety concerns with mAbs
In general, mAbs are well tolerated and, as noted earlier, have
some advantages over small molecules; they are more speciﬁc for
their target and do not interact with cytochrome P450 or other
transport proteins in the body, resulting in reduced potential for
drugedrug interactions.
Toxicity associated with mAbs can be related to the pharmaco-
logical activity of the mAb, due to a direct consequence of engaging
the target molecule (protein or receptor) or process within the
intended tissue. For example, the platelet aggregation inhibitor
abciximab is associated with an increased risk of minor bleeding
[25,31]. This AE is driven by the intended pharmacological action of
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IIb/IIIa). Alternatively, mAbs may cause toxicity by interacting with
the target antigen on tissues other than the intended tissue. For
example, skin toxicity associated with cetuximabea mAb that
inhibits epidermal growth factor receptor (EGFR) and is approved
for colorectal and head and neck cancereis thought to be related
to expression of the target antigen, EGFR, in human keratinocytes
[30]. Many of the safety proﬁles of mAbs are antigen/target-related
and will be speciﬁc to their target and therapeutic area of use.
Off-target, non-speciﬁc toxicity can also be observed with
mAbs; for example, hypersensitivity reactions are commonly
observed and are thought to be related to the immunogenicity of
mAbs. It is important to note that the main factor affecting mAb
immunogenicity is the proportion of human versus non-human
sequence [30,35]. Those mAbs with a high proportion of non-
human sequence are likely to be recognized as ‘foreign’ and
therefore induce a host immune response. This can result in
reduced efﬁcacy of the mAb, due to increased clearance, and AEs,
such as infusion or injection-site reactions. Production of mAbs
from human germline sequences and the development of fully
human mAbs can reduce the risk of immunogenicity but may not
completely eliminate it. This is because factors other than the pri-
mary sequence, such as mAb formulation, mAb aggregation
induced upon storage, protein conformation, glycosylation, impu-
rities arising from the production method, the container system
and storage conditions all contribute to immunogenic potential
[35]. The cell line used to manufacture the antibody can also make
a difference; for example, cetuximab produced in NS0 cells contains
alpha-galactose carbohydrate that can cause hypersensitivity re-
actions in some allergic individuals, while antibodies manufactured
in the widely-used Chinese Hamster Ovary (CHO) cells do not
contain this allergenic carbohydrate epitope [61].
Overall, the risk of serious adverse drug reactions (ADRs) with
mAbs is generally low [29,62e64]. A meta-analysis of studies
assessed the rates of adverse effects of nine biologics, alone or as
add-on therapy, in any indication (except HIV/AIDs) compared with
any other therapy or placebo in 163 randomized controlled trials
(RCTs) (n ¼ 50,010) and 46 extension studies (n ¼ 11,954). This
analysis suggested that biologics were associated with a sig-
niﬁcantly higher rate of total ADRs versus other therapy or placebo
(odds ratio [OR] 1.19, 95% CI [conﬁdence interval] 1.09e1.30);
however, the rates of serious adverse events (SAEs), serious in-
fections, lymphoma and heart failure were not signiﬁcantly differ-
ent from what was seen with the control arm (placebo or other
therapy) in these studies [29]. It should also be noted that this
analysis does not separate on-target and off-target AEs. It is likely
that the majority of the ADRs reported in the studies were related
to on-target toxicity, which is speciﬁc to the mAb used and the
therapy area it was used in. Although the studies included in this
analysis were of short duration (median 6 months for RCTs and 13
months for open-label extension studies), previous studies suggest
that mAb safety proﬁles remain relatively unchanged during the
long term [62e64]. Additionally, there are some real-life data
indicating that mAbs for rheumatoid arthritis and Crohn’s disease
arewell tolerated over the long-term [65,66]. Some examples of the
better-known mAb safety concerns, both on-target and off-target,
are described in Table 2.
4. mAbs for the treatment of CVD
As noted earlier, CVD is one of the major causes of death and
disability in Western societies. To date, few mAbs have been
developed for the treatment of CVD or its risk factors; however,
with several agents in development, this is likely to change in the
near future.4.1. Abciximab
Abciximab, a Fab fragment from a chimeric mAb, was licensed in
the United States in 1994 for use in patients undergoing percuta-
neous coronary intervention (PCI). It inhibits platelet cross-linking
and aggregation by targeting glycoprotein IIb/IIIa, thereby reducing
blood coagulability [75,76]. Abciximab is an intravenously admin-
istered drug that is used only in hospitals by interventional cardi-
ologists. Abciximab is associated with off-target, non-speciﬁc AEs,
such as the formation of HAMAs leading to hypersensitivity, a likely
consequence of not being a fully human mAb. The agent also leads
to on-target AEs, such as an increased risk of bleeding and
thrombocytopaenia [21,77].
4.2. PCSK9 mAbs
PCSK9 plays an important role in the regulation of plasma levels
of atherogenic LDL-C. In healthy humans, approximately 70% of LDL
particles are removed from the circulation via hepatic uptake, more
than 90% of which is mediated by the transmembrane LDL receptor
(LDLR) [78]. Each LDLR binds a single LDL particle and is internal-
ized by endocytosis [78]. A drop in pH causes the LDL to separate
from its receptor in the endosomes and the unoccupied receptors
are returned to the cell surface for reuse. At the same time, the
lipoprotein is degraded and the released cholesterol is stored in the
cell and used for a variety of cellular activities. In the hepatocyte,
these are primarily the production of bile acids and very-low-
density lipoprotein (VLDL). Each cycle takes about 12 min and,
since the LDLR has a lifespan of about 30 h, each LDLR may recycle
around 150 times [79]. As a result, minor decreases in LDLR activity
can result in major increases in plasma LDL-C levels.
The level of hepatic LDLR is controlled at the transcriptional
level via sterol regulatory element-binding protein 2 (SREBP-2) and
at the post-transcriptional level via PCSK9 (Fig. 2A) [37,38,80e83].
PCSK9 is the ninth member of the subtilisin family of serine pro-
teases and is mainly expressed in the liver and intestine [84]. Fol-
lowing secretion, it binds to LDLRs and stimulates receptor
internalization. This process leads to increased LDLR degradation,
reduced availability of transmembrane LDLRs, and increased levels
of plasma LDL-C [85]. As described below, people with a mutation
in PCSK9 that prevents its ability to interact with LDLR (loss of
function in PCSK9) have lower LDL-C and, more importantly,
a dramatic reduction in CV events. Thus, blocking the interaction
between LDLRs and PCSK9 is likely to reduce CV risk in people with
hypercholesterolaemia by increasing the availability of cell-surface
LDLRs and reducing serum LDL-C (Fig. 2B).
Since the lipid-lowering efﬁcacy of statins is limited, at least in
part, by a statin-induced increase in PCSK9 expression [83,84], it is
anticipated that inhibiting the PCSK9eLDLR interaction may also
increase the lipid-lowering efﬁcacy of statins. The enzymatic ac-
tivity of secreted PCSK9 is not required for degradation of the LDLR,
making the development of small molecules that target this
enzyme difﬁcult [86]. Current approaches to inhibiting circulating
PCSK9 include mimetic peptides, nucleic acid technologies and
mAbs. Of these, nucleic acid technologies and mAbs have entered
clinical development.
Among the nucleic acid-based therapies, SPC5001 (Santaris
Pharma A/S), a locked nucleic acid-based inhibitor, and BMS-
844421 (Bristol-Myers Squibb), an antisense RNA therapy, have
terminated clinical trials [87,88]. ALN-PCS02 (Alnylam), an RNA
interference inhibitor, is currently in phase 1 clinical trials [89].
To date, clinical trials conducted for mAbs targeting PCSK9
have been quite successful. Phase 2 trial results are available for
the mAbs developed by Sanoﬁ/Regeneron (SAR236553/REGN727)
[90e92] and Amgen (mAb1/AMG145) [93e96]; the Sanoﬁ/
Table 2
Examples of safety concerns with monoclonal antibodies, across therapy areas.
AE Description Frequency and severity Mechanism
AEs due to inhibition of target antigen
Infections Ranging from mild upper respiratory tract
infections to serious infections such as
tuberculosis and invasive opportunistic infections
Mild infections common with
immunosuppressive antibodies
Generally reported for mAbs
designed to reduce the activity
of T cells and B cells, such as
inﬂiximab, adalimumab and
etanercept
Drug-induced thrombocytopaenia Low levels of platelets, often associated
with abnormal bleeding [67]
In patients treated with abciximab,
profound thrombocytopaenia occurs
in w1% with ﬁrst infusion and in w4%
after the ﬁrst exposure [68].
Generally reported for antibodies
used in the CV therapy area,
such as abciximab
Autoimmune diseases Includes lupus-like syndromes, vasculitis,
nephritis, demyelinating syndromes,
thyroid disease and autoimmune colitis [18,69]
Uncommon, and symptoms are often
reversed when therapy is stopped [69]
Often reported for mAbs used in
chronic inﬂammatory diseases
(due to their interference with
the immune system) [32]
Tumour lysis syndrome Group of metabolic abnormalities,
including hyperuricaemia, hyperkalaemia
Rare, but potentially serious Reported for mAbs used in cancer
therapy, such as rituximab.
Large number of tumour cells
lysed; if these are not eliminated
the intracellular content cause
metabolic disturbances
Off-target, non-speciﬁc AEs
Infusion reactions/injection-site
reactions
Includes mild injection-site skin reactions,
pyrexia and inﬂuenza-like symptoms [18,33]
Acute infusion reactions include anaphylactic
and anaphylactoid reactions, and systemic
inﬂammatory response syndrome [70]
Mild reactions common; can be
managed by early risk factor recognition,
appropriate monitoring and prompt
intervention [18,33]
Acute events are uncommon and risks
can be reduced by slowing the rate of
infusion [18,33]
Off-target, non-speciﬁc
Immunogenicity thought to be
less likely to occur for mAbs
with more human versus
non-human sequence [30]
Cell line used to manufacture
antibody can also have an
effect; for example, cetuximab
produced in cell containing
alpha-galactose carbohydrate
can cause hypersensitivity
reactions [61]
AEs due to antigen expression on normal tissue
Malignancies Some mAbs (e.g. inﬂiximab, tositumomab and
ibritumomab) have off-target tumour-promoting
anti-inﬂammatory effects [20]
Rare Exact link remains
controversial [18,71]
Cardiotoxicity Cardiac dysfunction, such as an asymptomatic
decrease in left ventricular ejection fraction
Heart failure observed in up to 4% of
women treated with trastuzumab and
10% of treated patients experience a
decrease in cardiac function. [72]
Usually reversible and patients
respond well to standard medical
management [73]
Thought to be due to the role
of the antigen HER2 in
cardiomyocyte survival [30]
Cytokine release syndrome Uncontrolled hypercytokinaemia Can cause inﬂuenza-type symptoms,
swelling and redness, and can be fatal
Caused by positive feedback
loops between cytokines and
immune cells resulting in
highly elevated levels of
proinﬂammatory cytokines [74]
Three mAbs identiﬁed that
cause cytokine release
syndrome in humans:
alemtuzumab, muromonab and
TGN1412 (withdrawn from
development) [18]
mAb, monoclonal antibody; HER2, human epidermal growth factor 2.
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development. A number of additional PCSK9 mAbs, in earlier
clinical development, are currently being investigated for po-
tential use in humans, including 1B20 (Merck & Co.; pre-clinical)
[97], PF-04950615/RN-316 (Pﬁzer; phase 2) and LGT 209
(Novartis; phase 2) [38] and MPSK3169A (Roche-Genentech,
Phase 2 [98].
5. Efﬁcacy and safety of PCSK9 mAbs
5.1. Epidemiological studies
The correlation between PCSK9 and LDL-C levels has been
associated, in part, with genetic variation in PCSK9 and more than50 amino acid variants of PCSK9 have been demonstrated to in-
ﬂuence plasma cholesterol levels [99]. Gain-of-function (GOF)
mutations in the gene encoding PCSK9 have been identiﬁed in
families with autosomal dominant familial hypercholesterolaemia
(FH). These mutations, which increase the afﬁnity of PCSK9 for
LDLR, result in high cholesterol levels and a signiﬁcantly increased
incidence of coronary heart disease [100]. For severemutations, the
onset of coronary artery disease may occur 10 years sooner than in
heterozygous FH patients with severe LDLR mutations [101]. Fur-
thermore, a polymorphism within the PCSK9 gene that is asso-
ciated with higher LDL-C levels has also been associated with
increased carotid artery intimaemedia thickness [102].
Conversely, in people with one PCSK9 allele with loss-of-
function (LOF) mutations that prevent productive interaction with
Fig. 2. The role of PCSK9 in the regulation of the LDLR. A. Levels of hepatic LDLRs are controlled by sterol regulatory element-binding protein 2 (at the transcriptional level) and by
PCSK9 (at the post-transcriptional level). PCSK9 binds to LDLRs and, upon internalization, directs the receptor to the lysosome for destruction, thus decreasing the level of LDLRs at
the cell surface. B. PCSK9 antibody prevents binding of PCSK9 to the LDLR-LDL complex, increasing the availability of cell-surface LDLRs.
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heart disease is reduced by up to 88% [103e106]. An analysis of
three studies conducted in Copenhagen showed that the PCSK9
R46L allele is associatedwith lower LDL-C levels than thosewithout
this allele. This was observed in all age groups, and the PCSK9 R46L
genotypewas also associatedwith a reduced risk of ischaemic heart
disease and mortality [107]. The ARIC study also showed that car-
riers of PCSK9 variants that were associatedwith lower LDL-C levels
had a lower incidence of peripheral arterial disease [108].
Patientswith LOF PCSK9mutations are generally healthywith no
other apparent metabolic abnormalities. Three examples of in-
dividuals with no detectable circulating PCSK9 have been reported.
One subjectwho had inactivatingmutations in PCSK9 in both alleles
had an LDL-C of 14mg/dL, butwas otherwise healthy, normotensive
and had normal liver and renal function tests [104]. Another indi-
vidual with a double mutation affecting the same PCSK9 allele,
which had dominant negative activity, had an LDL-C of 16 mg/dL;
this individual had diabetes, of uncertain aetiology, but had normal
hepatic enzyme levels and liver function tests. Additionally, results
from this individual showed for the ﬁrst time that a PCSK9 loss-of-
function mutation resulted in increased LDL catabolism in humans
[109]. A third subject was homozygous for the C679X mutation of
PCSK9 and had an LDL-C of 15mg/dL [110]. Additionally, no obvious
phenotypic abnormalities have been identiﬁed in PCSK9 knockout
mice [111]. This currently suggests that use of PCSK9 mAbs is un-
likely to be associated with on-target AEs [38].
Aside from speciﬁc GOF or LOF mutations, overall serum PCSK9
levels in subjects have also been directly correlated with serum
concentrations of LDL-C and with total cholesterol [112,113]. A
study of patients with FH who have a pathogenic mutation in the
LDLR or ApoB gene, and were not receiving cholesterol-lowering
treatment, suggested that PCSK9 may contribute to the pheno-
typic severity of FH. In this study, PCSK9 plasma levels were sig-
niﬁcantly lower in patients with an LDL-C level below the 75th
percentile than in patients with LDL-C above the 90th percentile
[114]. PCSK9 levels were also found to be closely associated with
LDL-C levels across all groups [114].
5.2. Pre-clinical studies
Pre-clinical studies in wild-type mice show that a single intra-
venous injection of AMG145 (Amgen’s fully human PCSK9mAb) can
increase hepatic LDLR protein levels roughly two-fold and lower
serum total cholesterol by up to 36%, an effect not seen in LDLR
knockout mice [115]. In cynomolgus monkeys, a single intravenous
injection of the same mAb reduced serum LDL-C by up to 80% and
maintained a signiﬁcant decrease for 10 days [115]. Similar results
were also obtained in rodents and primates using PCSK9mAbs from
Sanoﬁ/Regeneron (SAR236553/REGN727) [116], Pﬁzer (J10, J16)
[117,118], and Merck & Co (1D05-IgG2 and 1B20) [97,119,120].
Moreover, whereas a twice-daily dose of atorvastatin had little ef-
fect on serum LDL-C levels in statin-resistant male Syrian hamsters,
a single subcutaneous injection of SAR236553/REGN727 dose-
dependently neutralized PCSK9 activity and reduced LDL-C by up
to 58%. In this study, SAR236553/REGN727 was well tolerated, with
no clinically relevant effects on safety parameters, liver weight,
hepatic cholesterol, triglycerides or phospholipid concentrations.
This suggests that, in addition to dose-dependently reducing LDL-C
by neutralizing PCSK9 activity, SAR236553/REGN727 can overcome
the statin resistance observed in hamsters [121].
5.3. Phase 1 studies
Phase 1 studies in humans have shown that PCSK9 mAbs are
well tolerated and signiﬁcantly reduce LDL-C levels in healthysubjects and patients with hypercholesterolaemia [122e125]. Sin-
gle doseeresponse studies with Sanoﬁ-Regeneron’s fully human
mAb SAR236553/REGN727, for example, showed that intravenous
or subcutaneous injections dose-dependently reduced mean LDL-C
levels by up to 65% in healthy volunteers with LDL-C >2.6 mmol/L
(>100 mg/dL), an effect that was maintained for at least 30 days
with the higher doses [124]. A further phase 1 multiple-dose study
assessed SAR236553/REGN727, administered by subcutaneous in-
jection (50, 100 or 150 mg) in patients with hypercholesterolaemia
(FH or non-FH) receiving statins and those with non-FH receiving
diet therapy [124]. As an add-on therapy to a statin, SAR236553/
REGN727 was associated with reductions from baseline in LDL-C of
41e58% in patients with FH, and reductions of 38e65% in those
without FH. In non-FH patients receiving diet therapy only,
SAR236553/REGN727 was associated with a 57% reduction from
baseline in LDL-C levels [124].
A phase 1a study of Amgen’s AMG145 mAb showed that single
subcutaneous and intravenous injections dose-dependently
reduced LDL-C by up to 64% versus placebo (P < 0.0001) in
healthy volunteers [125]. In a phase 1b dose-escalation study, pa-
tients with hypercholesterolaemia (FH or non-FH) were given
repeated doses of AMG145 subcutaneously as add-on therapy to
statins (low- to moderate-dose or high-dose) [125]. Over 6e8
weeks, administration of AMG145 resulted in dose-dependent re-
ductions in LDL-C up to 75% versus placebo in patients receiving
low- to moderate-dose statins [125]. Similar reductions in LDL-C
were observed in patients with heterozygous FH (65% versus
placebo) and those receiving high-dose statins (63% versus pla-
cebo) [125].
In each of the phase 1 studies for SAR236553/REGN727 and
AMG145, treatments were generally well tolerated, with no clin-
ically meaningful elevations in liver transaminases or other safety
parameters [124,125]. During the multiple-dose study of
SAR236553/REGN727 no SAEs were reported. Although two pa-
tients in the single-dose SAR236553/REGN727 studies experienced
SAEs (abdominal pain with rectal bleeding and a small-bowel
obstruction in a patient with prior appendectomy), neither resul-
ted in study discontinuation, nor were they considered related to
study treatment [124]. In the SAR236553/REGN727 intravenous
study, the incidence of treatment-emergent adverse events
(TEAEs) was similar among subjects treated with study drug and
those treated with placebo [124]. Compared with placebo, a higher
proportion of patients treated with single dose and multiple doses
of subcutaneous SAR236553/REGN727 experienced an AE. No
speciﬁc pattern of AEs was identiﬁed, but headache was the most
common event. The few reported injection-site reactions were
mild in severity and most were transient [124]. For AMG145, no
SAEs were reported and the incidence of TEAEs was similar among
subjects treated with AMG145 and those treated with placebo
[125]. Furthermore, no patients discontinued due to AEs and there
did not appear to be any relationship between the incidence of AEs
and the dose of AMG145 [125].
5.4. Phase 2 studies
Phase 2 clinical studies evaluating SAR236553/REGN727 have
recently completed. The ﬁrst of these studies compared the ef-
fects of ﬁve different dosing regimens of SAR236553/REGN727
versus placebo in patients with primary hypercholesterolaemia
(LDL-C 2.6 mmol/L) who were on stable atorvastatin therapy
[90]. This was a double-blind, parallel-group, placebo-controlled
trial in which 183 patients were randomized to placebo or one
of the SAR236553/REGN727 regimens (50, 100 or 150 mg every 2
weeks, or 200 or 300 mg every 4 weeks) for 12 weeks [90]. After
12 weeks, LDL-C levels decreased signiﬁcantly from baseline by
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and 150 mg every 2 weeks (P < 0.0001 for all dose groups versus
placebo). In those receiving SAR236553/REGN727 200 mg or
300 mg every 4 weeks, the reductions in LDL-C observed 2 weeks
after each dose (67% and 70% reductions from baseline) waned
over the following 2 weeks to 39% and 53% reductions from
baseline. This suggests that the every-2-weeks regimen may have
the maximum effect and be the most favourable regimen, deliv-
ered using a single subcutaneous injection [90]. Between 89% and
100% of SAR236553/REGN727 recipients achieved the target LDL-
C of <100 mg/dL, compared with 16% of those receiving placebo.
Furthermore, LDL-C levels of <70 mg/dL were achieved by be-
tween 46 and 100% of SAR236553/REGN727 recipients versus 3%
of placebo recipients [90]. Although patients were receiving dif-
ferent atorvastatin doses (10, 20 or 40 mg), LDL-C reductions
were similar irrespective of atorvastatin dose [90].
The second of the phase 2 trials compared the LDL-C-lowering
efﬁcacy and safety of co-administering SAR236553/REGN727 ver-
sus placebo with high-dose atorvastatin (80 mg) in patients with
LDL-C 2.6 mmol/L (100 mg/dL) despite treatment with stable-
dose atorvastatin 10 mg for at least 6 weeks prior to random-
ization [92]. After 8 weeks, patients receiving atorvastatin 80 mg/
day plus a single subcutaneous dose of SAR236553/REGN727
administered every 2 weeks achieved a least-squares mean LDL-C
reduction of 73%, versus 17% for those on atorvastatin 80 mg plus
placebo (P < 0.001) [92]. The least-squares mean reduction from
baseline in LDL-C after 8 weeks with SAR236553/REGN727 plus
atorvastatin 10 mg was 66% [92].
LDL-C reductions were similar irrespective of statin dose. It has
been shown that statin treatment results in an increase in PCSK9
levels that limits their lipid-lowering efﬁcacy [126]. As such, co-
administration of SAR236553/REGN727 with atorvastatin may
beneﬁt patients that fail to achieve their LDL-C target using high-
dose statins. Moreover, since the additional reduction in LDL-C
with SAR236553/REGN727 appears to be similar irrespective of
atorvastatin dose, co-administration of SAR236553/REGN727 with
low-dose statins may beneﬁt patients who fail to achieve their LDL-
C targets owing to an intolerance of high-dose statins.
A third phase 2 study investigated the addition of various dosing
regimens of SAR236553/REGN727 to statins in patients with FH
[91]. Patients with FH on stable diet and statin dose, with or
without ezetimibe, were randomized to SAR236553/REGN727 150,
200 or 300 mg every 4 weeks, or 150 mg every 2 weeks, or placebo
every 2 weeks for a total of 12 weeks [91]. Administration of
SAR236553/REGN727 resulted in dose-dependent LS-mean LDL-C
reductions from baseline to week 12 of 29e68%, compared with
11% with placebo [91].
In all of the phase 2 studies, SAR236553/REGN727was generally
well tolerated over the treatment period, with no drug-related AEs
on liver function tests or other laboratory parameters, and no
serious TEAEs related to treatment [90e92]. Injection-site reactions
(including erythema, pruritus, swelling, haematoma and rash)were
the most common AEs in two of the phase 2 trials and were gen-
erally mild in severity [90]. However, in the phase 2 study assessing
SAR236553/REGN727 for treatment of FH, one patient, receiving
300 mg every 4 weeks, terminated the study after one dose due to
an injection-site reaction and generalized pruritus. No treatment
was required for this reaction and the patient did not experience
any residual effects [91]. Muscle complaints, including pain and
weakness, were infrequently reported in the ﬁrst phase 2 study,
and the incidence was similar across treatment groups. Fur-
thermore, increases in muscle-related enzymes were not observed
[90].
There was a single case of cutaneous leukocytoclastic vasculitis
(CLV) reported in one patient 9 days after initiation of SAR236553/REGN727 (300 mg). This event was diagnosed by biopsy and was
not associated with other organ involvement; the patient respon-
ded quickly to steroid therapy initiation and SAR236553/REGN727
discontinuation [90]. Anti-drug antibodies were not found follow-
ing the event; however, they were present at the 20-week follow-
up, although at a titer of 30, the minimum titer detectable by the
assay. CLV is a generally benign disease that occurs at the rate of
40e60 cases/million persons/year [127]. It appears to be caused by
immune complex deposition in vessel walls, leading to cellular
inﬁltrates, cytokine release and vessel damagewith bleeding. Drugs
implicated in the development of CLV include small molecules and
protein therapy (i.e. mAbs) [128]. In a review of articles published
between 1990 and 2008, there were 118 reported cases of CLV in
patients receiving mAbs against tumour necrosis factor [129].
AMG145 has been assessed in four phase 2 trials. AMG145 was
investigated as monotherapy in 406 patients with hyper-
cholesterolaemia (LDL-C between 2.6 and 4.9 mmol/L) [94]. In this
trial, patients received AMG145 70, 105 or 140 mg every 2 weeks or
280, 350, 420 mg every 4 weeks or matching placebo or ezetimibe
10 mg/day. At week 12, the change from baseline in LDL-C ranged
from39% to51% with AMG145 compared with3.7% andþ4.5%
for the two placebo regimens (every 2 weeks and every 4 weeks,
respectively) and 15% with ezetimibe (P < 0.0001 for all doses
versus placebo or ezetimibe) [94].
AMG145 was also assessed in 631 patients with hyper-
cholesterolaemia (LDL-C > 2.2 mmol/L) on a stable dose of statin,
with or without ezetimibe [93]. Patients were randomized to
AMG145 every 2 weeks (70, 105 or 140 mg) or every 4 weeks (280,
350 or 420 mg) or matching placebo. At week 12, AMG145 was
associated with dose-dependent reductions in mean LDL-C versus
placebo of 42e66% with the every-2-week regimen and 42e50%
with the every-4-week regimen [93].
In an another trial, 160 patients who were statin-intolerant due
to muscle-related side effects were randomized to treatment with
AMG145 280, 350 or 420mg alone; AMG145 420mg plus ezetimibe
10 mg or ezetimibe 10 mg plus placebo [96]. AMG145 or placebo
was administered every 4 weeks. After 12 weeks of treatment,
least-squares mean percentage changes in LDL-C from baseline
ranged from41 to51% in the AMG145 alone groups,63% in the
AMG145 420 mg/ezetimibe group and 15% for those receiving
placebo/ezetimibe [96].
Finally, AMG145 has also been assessed in patients with het-
erozygous FH. A total of 167 patients with heterozygous FH with
LDL-C 2.6 mmol/L despite statin treatment, with or without
ezetimibe, received treatment with either AMG145 350 or 420 mg
or placebo administered every 4 weeks [95]. At week 12, AMG145
350 and 420 mg were associated with a least-squares mean
reduction in LDL-C of 43% and 55%, respectively, compared with
a 1% increase with placebo [95].
Overall, AMG145 was generally well tolerated throughout the
phase 2 trials, with a similar incidence of treatment-related AEs
across treatment groups, and no evidence of a relationship between
the incidence of any particular AE and AMG145 dose [93e96].
Injection-site reactions were observed with AMG145 but were
generally infrequent and not severe [93e96].
Other phase 2 studies have also completed enrolment, including
a multiple-dose study of PF-04950615 [130].
While the development of mAbs targeting PCSK9 for the treat-
ment of hypercholesterolaemia is still in its early stages, current
data indicate that a fully human mAb for this target demonstrates
clinically meaningful reductions in LDL-C in patients treated with
and without statins. Current data also have not revealed potential
on-target adverse effects of blocking PCSK9 and appear to avoid the
apparent on-target effects of inhibiting HMG CoA reductase with
statins: muscle toxicity and liver aminotransferase elevations. The
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actions and immunosensitivity reactions but some potential for
these AEs still exist. However, the current conclusions are based
upon phase 1 and 2 trials of limited exposure and from relatively
small patient populations. Clinical trials of larger size and longer
duration, in more varied patient populations, are ongoing to further
assess the efﬁcacy and safety of mAbs targeting PCSK9. For exam-
ple, the ODYSSEY phase 3 programme will assess SAR236553/
REGN727 in more than 22,000 patients [131]. This includes trials
assessing the effect of SAR236553/REGN727 on lowering LDL-C
levels in varied patient populations, including those at elevated
cardiovascular risk [132], those unable to tolerate statins [133],
those with FH [134] and a cardiovascular outcomes study [135].
6. Conclusions
mAbs have been used in clinical practice for many years, and are
established therapies for cancers, autoimmune conditions and in-
fectious disease. mAbs offer clear beneﬁts over conventional
pharmacotherapy in terms of their potential for potency, dosing
frequency, and speciﬁcity to their target antigen. Initially, mouse
antibodies were developed, but many patients treated with these
developed HAMAs, resulting in rapid clearance of the mAb, loss of
efﬁcacy and hypersensitivity reactions. Chimeric and humanized
mAbs, with increasing amounts of human sequence, have thus been
developed to reduce the risk of immunogenicity. Most recently,
fully humanmAbs have been developed; it is anticipated that these
may reduce immunogenicity further. Although generally well tol-
erated, mAbs are associated with AEs. Some of these, such as mild
hypersensitivity reactions, are commonly observed with many
mAbs, while more serious hypersensitivity reactions occur less
frequently. In contrast, other AEs are antigen related and will be
speciﬁc to the target of the mAb and the therapeutic area of use.
Therefore, it will be important to consider the mechanism of action
of each mAb and fully assess their efﬁcacy and safety in clinical
trials.
mAbs are now being investigated for the reduction of LDL-C in
subjects with hypercholesterolaemia by targeting PCSK9. PCSK9
plays a major role in the regulation of LDL-C levels via its inter-
actionwith the LDLR. The reduced incidence of CV events in healthy
patients with PCSK9 LOF mutations suggests that inhibiting the
interaction between PCSK9 and LDLR has great potential for the
management of patients with severe and/or refractory hyper-
cholesterolaemia. Initial safety assessments of PCSK9mAbs showed
that these molecules were generally well tolerated. However, fur-
ther studies are required to assess the long-term safety of this
potential new drug class in a wider range of patients. Based on the
current ﬁndings, PCSK9 mAbs may be of particular use for patients
with hypercholesterolaemia who are unable to achieve LDL-C tar-
gets or those who are intolerant to currently available treatment
options.
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